Executive Summary
Across the 5 filings in the USA S&P 500 Energy intelligence stream (with contextual non-energy inclusions), overarching themes include mixed financial performance highlighted by robust YoY earnings growth in Kinder Morgan (36% net income, 39% Adj NI) and Peapack-Gladstone (86% net income), contrasted by volume declines in energy transport and persistent cash burn in smaller entities like Hestia. Period-over-period trends show strong top-line expansion (Kinder Adj EBITDA +18% YoY, Peapack NII +32% YoY) but deteriorating operational metrics (Kinder refined volumes -2% YoY, crude -12% YoY; Hestia revenue flat at $0). Critical developments feature Kinder Morgan's $505M Monument Pipeline acquisition, 2% dividend hike to $0.2975/share, Moody's Baa1 upgrade, and flat 2026 net income guidance at $3.1B amid 2-5% adjusted growth; Stoke Therapeutics' proxy filings signal upcoming governance votes. Portfolio-level patterns reveal sector resilience in midstream energy via backlog growth ($10.1B, +$145M QoQ) and capital returns, but caution from asset-specific volume pressures and banking credit risks spilling into energy financing context. Market implications point to selective bullishness in pipelines with high utilization (90% in 2025 vs 74% 2016), tempered by flat outlooks and mixed sentiment (3/5 filings).
Tracking the trend? Catch up on the prior S&P 500 Energy Sector SEC Filings digest from April 15, 2026.
Investment Signals(11)
- Kinder Morgan↓(BULLISH)▲
Q1 2026 net income +36% YoY to $976M, Adj EBITDA +18% YoY to $2,539M, Adj EPS +41% YoY to $0.48, driven by Natural Gas Pipelines; project backlog $10.1B (+$145M QoQ) at 5.6x EBITDA multiple
- Kinder Morgan↓(BULLISH)▲
2% dividend increase to $0.2975/share, signaling strong capital allocation and shareholder returns amid Net Debt/EBITDA stable at 3.6x (expected 3.8x YE2026); Moody's upgrade to Baa1 enhances credit profile
- Peapack-Gladstone↓(BULLISH)▲
Q1 2026 net income +86% YoY to $14.2M ($0.80 EPS), NII +32% YoY to $59.9M, NIM +18 bps QoQ to 3.26%, loans +12% YoY to $6.4B, deposits +9% YoY to $6.8B
- Hestia Insight↓(BULLISH)▲
Q1 2026 net income turnaround to $3,152 profit from -$392K YoY loss, driven by $45,781 investment gain; op ex -64% YoY, total assets +9% QoQ to $429K
- Kinder Morgan↓(BULLISH)▲
Natural gas pipeline utilization 90% in 2025 (vs 74% 2016), supporting Adjusted metrics growth outlook of 2-5% for 2026 despite flat net income guidance
- Peapack-Gladstone↓(BULLISH)▲
Total revenue +28% YoY to $82.5M, loan-to-deposit ratio 94%, liquidity $5.0B (240% uninsured deposits), redeemed $100M subordinated debt
- Stoke Therapeutics (DEF 14A)(NEUTRAL-BULLISH)▲
Routine proxy for June 3, 2026 AGM with director elections and auditor ratification, 62M shares outstanding (record Apr 7), neutral governance signaling stability
- Kinder Morgan↓(BULLISH)▲
$505M Monument Pipeline acquisition enhances midstream assets amid $8.9B backlog (ex-CO2), positioning for EBITDA multiple expansion
- Peapack-Gladstone↓(BULLISH)▲
Balance sheet liquidity $991M (13% assets), supporting 12% YoY loan growth outpacing sector deposit betas
- Hestia Insight↓(BULLISH)▲
Stockholders' equity + to $120K amid investment portfolio growth offsetting op loss, related party support via $25K proceeds
- Stoke Therapeutics (DEFA14A)(NEUTRAL-BULLISH)▲
Additional proxy reinforces governance continuity for 2029 director terms, low materiality but confirms virtual AGM readiness
Risk Flags(9)
- Kinder Morgan/Volumes↓[HIGH RISK]▼
Refined products volumes -2% YoY, crude/condensate -12% YoY in Q1 2026, pressuring transport metrics despite earnings growth
- Kinder Morgan/Guidance↓[MEDIUM RISK]▼
2026 net income outlook flat at $3.1B despite modest 2-5% adjusted growth, signaling potential offset from volumes or costs
- Peapack-Gladstone/Credit↓[HIGH RISK]▼
Q1 2026 charge-offs $11.3M, provision for credit losses $7.3M, past due loans 0.73% (uptrend), despite earnings growth
- Peapack-Gladstone/Wealth↓[MEDIUM RISK]▼
AUM flat QoQ at $13.1B, non-interest revenue stagnation amid 28% total revenue growth driven solely by NII
- Hestia Insight/Cash Burn↓[HIGH RISK]▼
Cash -41% QoQ to $17K, net cash used in ops $36.8K (similar YoY), revenue $0 both periods, ongoing operating loss $39K
- Hestia Insight/Debt↓[HIGH RISK]▼
Related party loan payable +14% QoQ to $198K (total liabilities +11% to $309K), dependency on $25K proceeds highlights liquidity strain
- Kinder Morgan/Debt↓[MEDIUM RISK]▼
Net Debt-to-Adj EBITDA 3.6x (expected 3.8x YE2026), moderate leverage but vulnerable to flat guidance and volume declines
- Peapack-Gladstone/NIM Trend↓[MEDIUM RISK]▼
NIM expansion +18 bps QoQ to 3.26% but QoQ NII growth only 6% vs 32% YoY, potential peaking in rate environment
- Stoke Therapeutics/Governance↓[LOW RISK]▼
Dual proxy filings (DEF 14A/DEFA14A) with no financials disclosed, potential for advisory say-on-pay rejection if compensation concerns arise
Opportunities(10)
- Kinder Morgan/Acquisition↓(OPPORTUNITY)◆
$505M Monument Pipeline deal at implied attractive valuation vs $8.9B backlog (5.6x EBITDA), accretive to midstream growth
- Kinder Morgan/Backlog↓(OPPORTUNITY)◆
$10.1B projects (+$145M QoQ), 90% utilization trend since 2016, positions for 2-5% adjusted growth in 2026
- Peapack-Gladstone/Loan Growth↓(OPPORTUNITY)◆
12% YoY loans to $6.4B outpacing 9% deposits, 94% L/D ratio with $5B liquidity offers NIM expansion alpha
- Kinder Morgan/Dividend↓(OPPORTUNITY)◆
2% hike to $0.2975/share post strong Q1 (+36% earnings), Baa1 upgrade supports sustained returns vs peers
- Hestia Insight/Turnaround↓(OPPORTUNITY)◆
Net income swing to +$3K from -$392K YoY via investments, op ex -64% sets stage for breakeven if revenue materializes
- Peapack-Gladstone/Redeem Debt↓(OPPORTUNITY)◆
$100M subordinated debt redemption strengthens capital, EPS +86% YoY enables M&A or buybacks
- Stoke Therapeutics/AGM↓(OPPORTUNITY)◆
June 3, 2026 virtual meeting with director elections to 2029, ratify E&Y auditors; vote on exec comp could signal alignment
- Kinder Morgan/COO Succession↓(OPPORTUNITY)◆
Retirement and succession announced, potential for operational refresh amid 18% EBITDA growth
- Peapack-Gladstone/Liquidity↓(OPPORTUNITY)◆
$991M core + $5B total liquidity (240% uninsured deps), undervalued for energy sector lending exposure
- Hestia Insight/Investments↓(OPPORTUNITY)◆
+$45K fair value gain drove profit, assets +9% QoQ; monitor for asset appreciation alpha in micro-cap
Sector Themes(6)
- Earnings Momentum(BULLISH IMPLICATION)◆
3/5 filings show strong YoY net income growth (Kinder +36%, Peapack +86%, Hestia turnaround from loss), avg +53% but mixed by energy vs financials; implies sector resilience post-volatility
- Volume/Op Headwinds(BEARISH IMPLICATION)◆
Energy transport declines (Kinder refined -2% YoY, crude -12%) contrast banking loan +12% YoY; highlights midstream pressures vs lending tailwinds
- Capital Returns Focus(NEUTRAL IMPLICATION)◆
Kinder 2% dividend hike amid $10.1B backlog; Peapack debt redemption; pattern of returns over reinvestment (no buybacks noted), stable Debt/EBITDA 3.6-3.8x
- Mixed Sentiment Dominates(CAUTIOUS IMPLICATION)◆
3/5 mixed (Kinder, Peapack, Hestia) due to growth offset by volumes/credit/cash burn; neutral proxies (Stoke); avg materiality 7.2/10 flags selective opportunities
- Guidance Stability(BULLISH IMPLICATION)◆
Kinder flat $3.1B 2026 net income but +2-5% adjusted; no cuts but modest vs Q1 beats, building catalyst for backlog execution
- Liquidity Strains in Small Caps[RISK IMPLICATION]◆
Hestia cash -41% QoQ, related debt +14%; contrasts Peapack's $5B liquidity; theme of funding dependency outside core energy giants
Watch List(8)
- Stoke Therapeutics/AGM↓(WATCH)👁
Monitor June 3, 2026 virtual meeting for director elections (Kahn, Krainer, Smith to 2029), auditor ratification, say-on-pay vote; results by mid-June
- Kinder Morgan/Guidance↓(WATCH)👁
Flat 2026 net income $3.1B vs 2-5% adjusted growth; track Q2 earnings for volume recovery and Debt/EBITDA to 3.8x
- Kinder Morgan/Acquisition↓(WATCH)👁
$505M Monument Pipeline integration; watch project backlog evolution to $10.1B+ and EBITDA multiple impacts Q2 2026
- Peapack-Gladstone/Credit↓(WATCH)👁
Past dues 0.73%, $11.3M charge-offs, $7.3M provisions; monitor Q2 for trend deterioration amid 12% loan growth
- Hestia Insight/Cash↓(WATCH)👁
$17K cash post -41% QoQ, $36.8K op burn; watch related party loans ($198K) and revenue emergence in next 10-Q
- Kinder Morgan/Utilization↓(WATCH)👁
90% nat gas pipelines in 2025; track Q2 volumes vs -2/-12% Q1 declines for midstream rebound signals
- Peapack-Gladstone/NIM↓(WATCH)👁
3.26% +18 bps QoQ; monitor Q2 for sustained expansion or peak amid deposit growth
- Stoke Therapeutics/Proxy↓(WATCH)👁
DEFA14A materials deadline May 20, 2026; watch voting turnout and outcomes for governance risks
Filing Analyses(5)
22-04-2026
Stoke Therapeutics, Inc. (STOK) filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 3, 2026 at 9:00 a.m. ET, with a record date of April 7, 2026 when 62,271,082 shares of common stock were outstanding. Stockholders will vote to elect three Class I directors (G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith) to serve until the 2029 annual meeting, ratify Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and approve on an advisory basis the compensation of named executive officers. No financial performance metrics or period-over-period changes are detailed in the filing.
- ·Virtual Annual Meeting access at www.virtualshareholdermeeting.com/STOK2026 (requires 16-digit control number).
- ·Proxy materials and 2025 Form 10-K available at https://investor.stoketherapeutics.com/financials-and-sec-filings.
- ·Transfer agent contact: Equiniti Trust Company, LLC at (800) 468-9716 or www.equiniti.com.
22-04-2026
Kinder Morgan reported Q1 2026 net income attributable to KMI of $976 million, up 36% YoY from $717 million, Adjusted Net Income of $1,063 million (up 39%), Adjusted EBITDA of $2,539 million (up 18%), and Adjusted EPS of $0.48 (up 41%), driven by strong Natural Gas Pipelines performance. However, refined products volumes declined 2% YoY and crude/condensate volumes fell 12% YoY, while 2026 net income outlook remains flat at $3.1 billion despite modest 2-5% growth in adjusted metrics. The company approved a 2% higher dividend of $0.2975 per share, received a Moody's upgrade to Baa1, announced COO retirement and succession, and agreed to acquire Monument Pipeline for $505 million.
- ·Net Debt-to-Adjusted EBITDA ratio ended Q1 2026 at 3.6 times; expected 3.8 times at end-2026.
- ·Project backlog $10.1B, up $145M from Q4 2025; $8.9B (ex-CO2/gathering) with 5.6x first-full-year Project EBITDA multiple.
- ·Annual average utilization of five major natural gas pipeline systems reached 90% in 2025 vs 74% in 2016.
- ·Moody’s upgraded senior unsecured rating to Baa1 (stable outlook) on March 12, 2026.
- ·James Holland retiring as COO effective September 4, 2026; succeeded by Ken Grubb.
22-04-2026
Peapack-Gladstone Financial Corporation reported Q1 2026 net income of $14.2 million ($0.80 diluted EPS), up 16% QoQ from $12.2 million and 86% YoY from $7.6 million, with net interest income rising 6% QoQ and 32% YoY to $59.9 million and NIM expanding 18 bps QoQ to 3.26%. Loans grew 12% YoY to $6.4 billion and deposits 9% YoY to $6.8 billion, while total revenue increased 28% YoY to $82.5 million. However, wealth management AUM remained flat at $13.1 billion, past due loans rose to 0.73% of loans, charge-offs totaled $11.3 million, and provision for credit losses was $7.3 million.
- ·Redeemed $100.0 million subordinated debt in Q1 2026.
- ·Loan-to-deposit ratio of 94% at March 31, 2026.
- ·Balance sheet liquidity $991 million (13% of total assets); total liquidity $5.0 billion (240% of uninsured/uncollateralized deposits).
- ·Declared cash dividend of $0.05 per share payable May 21, 2026.
- ·Conference call scheduled April 23, 2026 at 11:00 a.m. (ET).
22-04-2026
Hestia Insight Inc. reported net income of $3,152 for the three months ended February 28, 2026, a significant turnaround from a $392,295 net loss in the prior year period, driven by a $45,781 gain in fair value of investments offsetting a $39,326 operating loss; however, revenue remained at $0 in both periods, operating expenses declined 64% YoY but still resulted in an operating loss, and cash decreased 41% QoQ to $17,084 amid ongoing cash used in operations. Total assets grew 9% QoQ to $429,122, primarily from higher investments, while total liabilities rose 11% to $309,088 due to increased related party debt, and stockholders' equity improved slightly to $120,034.
- ·Related party loan payable increased to $198,931 from $173,931 QoQ.
- ·Net cash used in operating activities was $36,787, similar to $36,047 prior year.
- ·Proceeds from related party loan: $25,000 in the current period.
22-04-2026
Stoke Therapeutics, Inc. (STOK) filed a DEFA14A additional proxy statement ahead of its 2026 annual stockholder meeting on June 3, 2026, at 9:00 AM ET, held virtually. Shareholders are voting on the election of three Class I directors to serve until the 2029 annual meeting: G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith; ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026; and an advisory vote to approve named executive officer compensation.
- ·Materials request deadline: May 20, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
- ·Virtual meeting URL: www.virtualshareholdermeeting.com/STOK2026
- ·Directors to serve until 2029 annual meeting or successor election/resignation/removal
Get daily alerts with 11 investment signals, 9 risk alerts, 10 opportunities and full AI analysis of all 5 filings
More from: S&P 500 Energy Sector SEC Filings
🇺🇸 More from United States
View all →April 15, 2026
US Pre-Market SEC Filings Roundup — April 15, 2026
US Pre-Market SEC Filings Roundup
April 15, 2026
US Merger & Acquisition SEC Filings — April 15, 2026
US Merger & Acquisition SEC Filings
April 15, 2026
US Corporate Board Director Changes SEC Filings — April 15, 2026
US Corporate Board Director Changes SEC Filings
April 15, 2026
US Executive Officer Management Changes SEC — April 15, 2026
US Executive Officer Management Changes SEC